(Q38111620)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23732529%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23732529%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23732529%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

2

Catharina C Gross

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23732529%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

29 August 2017

language of work or name

English

0 references

publication date

4 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23732529%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

published in

Nature Reviews Neurology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23732529%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23732529%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23732529%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

394-404

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23732529%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Multiple sclerosis--the plaque and its pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Immune tolerance in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

The role of regulatory T cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Allelic expression and interleukin-2 polymorphisms in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Cytokines in genetic susceptibility to multiple sclerosis: a candidate gene approach. French Multiple Sclerosis Genetics Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

The biology of interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

The IL-2/IL-15 receptor systems: targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Intrathecal effects of daclizumab treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Long-term daclizumab therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Risk alleles for multiple sclerosis identified by a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

A function for interleukin 2 in Foxp3-expressing regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

The proteasome regulates receptor-mediated endocytosis of interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Daclizumab therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

CD56highCD16-CD62L- NK cells accumulate in allergic contact dermatitis and contribute to the expression of allergic responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Human natural killer cell development and biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

The biology of human natural killer-cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Human NK cells kill resting but not activated microglia via NKG2D- and NKp46-mediated recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Assessment of animal models for MS and demyelinating disease in the design of rational therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Functions of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Granzyme K cleaves the nucleosome assembly protein SET to induce single-stranded DNA nicks of target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Granzyme K displays highly restricted substrate specificity that only partially overlaps with granzyme A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Inflammatory cortical demyelination in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Innate lymphoid cells: emerging insights in development, lineage relationships, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Anti-CD25 immunotherapy: regulating the regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Anti-CD25 antibodies affect cytokine synthesis pattern of human dendritic cells and decrease their ability to prime allogeneic CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Teaching NeuroImages: 5-FU-induced acute leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

A function for IL-7R for CD4+CD25+Foxp3+ T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

FOXP3+ regulatory T cells in the human immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Intracellular signaling consequences of anti-IL-2Ralpha blockade by daclizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

IL-2 regulates expression of C-MAF in human CD4 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Lineage Relationship Analysis of RORγt+Innate Lymphoid Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Human IL-2 receptor alpha chain deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Daclizumab use in patients with pediatric multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Window of opportunity for daclizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Daclizumab for relapsing remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.95

Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23732529

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23732529